Inhibition of drug-naive and-resistant leukemia cell proliferation by low molecular weight thiols

Biochemical Pharmacology

Volumn 55, Issue 6, 1998, Pages 793-802

  Jeitner, Thomas M ^a,b   Delikatny, Edward J ^c   Bartier, Wendy A ^c   Capper, Hugh R ^c   Hunt, Nicholas H ^c  

^a ALBANY MEDICAL COLLEGE   (United States)

^b WADSWORTH CENTER   (United States)

^c NONE

Author keywords

Aminothiol; Cell cycle; Cysteamine; Drug resistance; Leukemia; Neoplasia

Indexed keywords

2 (3 AMINOPROPYLAMINO)ETHANETHIOL; ACETYLCYSTEINE; AMIFOSTINE; AMINOTHIOL; ANTILEUKEMIC AGENT; ANTIMITOTIC AGENT; CATALASE; CYSTAFOS; CYSTAMINE; CYSTEAMINE DERIVATIVE; DNA; ETHANOLAMINE; HYDROGEN PEROXIDE; METHOTREXATE; PENICILLAMINE; PHOSPHOROTHIOIC ACID S 2 (4 AMINOBUTYLAMINO)ETHYL ESTER; PHOSPHOROTHIOIC ACID S [2 (5 AMINOPENTYLAMINO)ETHYL] ESTER; SUPEROXIDE DISMUTASE; THIOCTIC ACID; THIOL DERIVATIVE; UNCLASSIFIED DRUG; UNITHIOL;

APOPTOSIS; ARTICLE; CELL CYCLE; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DRUG CONFORMATION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; LEUKEMIA CELL; MOLECULAR MODEL; OXYGEN CONSUMPTION; PRIORITY JOURNAL;

CELL DIVISION; DRUG RESISTANCE, NEOPLASM; HUMANS; LEUKEMIA; LINEAR MODELS; MERCAPTOETHANOL; MOLECULAR WEIGHT; OXYGEN CONSUMPTION; PEROXIDES; SULFHYDRYL COMPOUNDS; SUPEROXIDES; TUMOR CELLS, CULTURED;

EID: 0032520744     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(97)00575-3     Document Type: Article

References (51)

1. Yuhas JM. On the potential application of radioprotective drugs in solid tumor radiotherapy. Radiation-Drug Interactions in the Treatment of Cancer. 1980;113-135 John Wiley, New York.
2. Peterson TC, Peterson MR, Williams CN. The role of heme oxygenase and aryl hydrocarbon hydroxylase in the protection by cysteamine from acetaminophen hepatotoxicity. Toxicol Appl Pharmacol. 97:1989;430-439.
3. Prescott LF, Newton RW, Swainson CP, Wright N, Forrest ARW, Matthew H. Successful treatment of severe paracetamol overdosage with cysteamine. Lancet. 1:1974;588-592.
4. Liebert EL, Shannon MW. Oral chelators for childhood lead poisoning. Pediatr Ann. 23:1994;616-619.
5. Alberts DS, Bleyer WA. Future development of amifostine in cancer treatment. Semin Oncol. 23:1996;90-99.
6. Eberhardt K, Rydgren L, Fex E, Svensson B, Wollheim FA. D-Penicillamine in early rheumatoid arthritis Experience from a 2-year double blind placebo controlled study . Clin Exp Rheumatol. 14:1996;625-631.
7. Hulsewede JW, Schulte-Frohlinde D. Radiation protection of E. coli strains by cysteamine in the presence of oxygen. Int J Radiat Biol. 50:1986;861-869.
8. Brown PE. Mechanism of action of aminothiol radioprotectors. Nature. 213:1967;363-364.
9. Goutier R. Effects on cell growth processes (mitosis, synthesis of nucleic acids and of proteins). Bacq ZM. Sulfur-Containing Radioprotective Agents. 1975;283-301 Pergamon Press, Oxford.
10. Bryant HU, Holaday JW, Bernton EW. Cysteamine produces dose-related bidirectional immunomodulatory effects in mice. J Pharmacol Exp Ther. 249:1989;424-429.
11. Benke PJ, Levcovitz H, Paupe J, Tozman E. Scavengers of free radical oxygen affect the generation of low molecular weight DNA in stimulated lymphocytes from patients with systemic lupus erythematosus. Metabolism. 39:1990;1278-1284.
12. Zerek-Melen G, Sewerynek E, Szkudlinski M, Lewinski A, Krotewicz M, Fryczak J, Pawlikowski M. Suppressing effect of cysteamine on the TSH-stimulated mitotic activity of the rat thyroid follicular cells in vivo. Neuropeptides. 13:1989;171-174.
13. Jeitner TM, Kneale CL, Christopherson RI, Hunt NH. Thiol-bearing compounds selectively inhibit protein kinase C-dependent oxidative events and proliferation in human T cells. Biochim Biophys Acta. 1223:1994;15-22.
14. Goldstone SD, Fragonas JC, Jeitner TM, Hunt NH. Transcription factors as targets for oxidative signalling during lymphocyte activation. Biochim Biophys Acta. 1263:1995;114-122.
15. Jeitner TM, Renton FJ. Inhibition of the proliferation of human neural neoplastic cell lines by cysteamine. Cancer Lett. 103:1996;85-90.
16. Apffel CA, Walker JE, Issarescu S. Tumor rejection in experimental animals treated with radioprotective thiols. Cancer Res. 35:1975;429-437.
17. Laske R, Schonenberger H, Holler E. Investigations on the antiproliferative effects of amino acid antagonists targeting for aminoacyl-tRNA synthetases. Part II. The antileukaemic effect. Arch Pharm. 322:1989;857-862.
18. Watanabe H, Kamikawa H, Nakagawa Y, Takashi T, Ito A. The effects of ranitidine and cysteamine on intestinal neoplasia induced X-irradiation in rats. Acta Pathol Jpn. 38:1988;1285-1296.
19. Jeitner TM, Oliver JR. Possible oncostatic action of cysteamine on the pituitary glands of oestrogen-primed hyperprolactinaemic rats. J Endocrinol. 127:1990;119-127.
20. Tatsuta M, Iishi H, Baba M, Nakaizumi A, Uehara H, Taniguchi H. Enhancement by sulpiride of the inhibitory effects of cysteamine on gastric carcinogenesis induced by N-methyl-N′-nitro-N-nitrosoguanidine in Wistar rats. Int J Cancer. 47:1991;54-59.
21. Capozzi G, Modena G. Oxidation of thiols. Patai S. The Chemistry of the Thiol Group. 1974;785-840 John Wiley, London.
22. Biaglow JE, Issels RW, Gerweck LE, Varnes ME, Jacobson JB, Mitchell J, Russo A. Factors influencing the oxidation of cysteamine and other thiols Implication for hyperthermic sensitization and radiation protection . Radiat Res. 100:1984;298-301.
23. Tahsildar HI, Biaglow JE, Kligerman MM, Varnes ME. Factors influencing the oxidation of the radioprotector WR 1065. Radiat Res. 113:1988;243-251.
24. Staite ND, Messner RP, Zoschke DC. In vitro production and scavenging of hydrogen peroxide by D-penicillamine. Arthritis Rheum. 28:1985;914-921.
25. Starkebaum G, Root RK. D-Penicillamine Analysis of the mechanism of copper-catalyzed hydrogen peroxide generation . J Immunol. 134:1985;3371-3378.
26. Held KD, Biaglow JE. Mechanisms for the oxygen radical-mediated toxicity of various thiol-containing compounds in cultured mammalian cells. Radiat Res. 139:1994;15-23.
27. Taylor IW, Slowiaczek P, Friedlander ML, Tattersall MHN. Selective toxicity of a new lipophilic antifolate, BW301U, for methotrexate-resistant cells with reduced drug uptake. Cancer Res. 45:1985;978-982.
28. Haber M, Reed C, Kavallaris M, Norris MD, Stewart BW. Resistance to drugs associated with the multidrug resistance phenotype following selection with high concentration methotrexate. J Natl Cancer Inst. 81:1989;1250-1254.
29. Hida T, Ueda R, Takahashi T, Watanabe H, Kato T, Suyama M, Sugiura T, Ariyoshi Y, Takashi T. Chemosensitivity and radiosensitivity of small lung cancer cell lines by a newly developed 3-(4,5-dimethylthiazol-2-yl)-diphenyltetrazolium bromide (MTT) hybrid assay. Cancer Res. 49:1989;4785-4790.
30. Estabrook RW. Mitochondrial respiratory control and the polarographic measurement of ADP:0 ratios. Methods Enzymol. 10:1967;41-47.
31. Freshney RI, Culture of Animal Cells, Alan R. Liss, New York, 1987.
32. Collier HB. A note on the molar absorptivity of reduced Ellman's reagent, 3-carboxylato-4-nitrothiophenolate. Anal Biochem. 56:1973;310-311.
33. Heimer NE, Swanson JT and Stewart JP, MOPAC: Protected mode, Frank J. Seiler Research Laboratory, Colorado Springs, CO, 1993.
34. Huschtscha LI, Jeitner TM, Andersson CE, Bartier WA, Tattersall MHN. Identification of apoptotic and necrotic human leukemic cells by flow cytometry. Exp Cell Res. 212:1994;161-165.
35. Huschtscha LI, Bartier WA, Malmstrom A, Tattersall MHN. Cell death by apoptosis and necrosis following anticancer drug treatment in vitro. Int J Oncol. 6:1995;585-593.
36. Jencks WP, Regenstein J. Ionization constants of acids and bases. Fasman GD). Handbook of Biochemistry and Molecular Biology. 1976;346 CRC Press, Cleveland, OH.
37. Vergroesen AJ, Budke L, Vos O. Protection against X-irradiation by sulphydryl compounds. II. Studies on the relation between chemical structure and protective activity for tissue culture cells. Int J Radiat Biol. 13:1967;77-92.
38. Schreck R, Rieber P, Baeuerle PA. Reactive oxygen intermediates as apparently widely used messengers in the activation of the NF-κB transcription factor and HIV-1. EMBO J. 10:1991;2247-2258.
39. Sigdestad CP, Guilford W, Perrin J, Grdina DJ. Cell cycle redistribution of cultured cells after treatment with chemical radiation protectors. Cell Tissue Kinet. 21:1988;193-200.
40. Hohn-Elkarim K, Muhlensiepen H, Altman KI, Feinendegen LE. Modification of effects of radiation on thymidine kinase. Int J Radiat Biol. 58:1990;97-110.
41. Billen D. The effects of radioprotectors on DNA polymerase I-directed repair synthesis and DNA strand breaks in toulene-treated and X-irradiated Escherichia coli. Radiat Res. 95:1983;158-164.
42. Tisdale MJ, Mahmoud MB. Activities of free radical metabolizing enzymes in tumours. Br J Cancer. 47:1983;809-812.
43. Takagi Y, Shikitat T, Terasima T, Akaboshi S. Specificity of radioprotective and cytotoxic effects of cysteamine in HeLa S3 cells Generation of hydrogen peroxide . Radiat Res. 60:1974;292-301.
44. Meier T, Issels RD. Degradation of 2-(3-aminopropylamino)-ethanethiol (WR-1065) by Cu-dependent amine oxidases and influence on glutathione status of Chinese hamster ovary cells. Biochem Pharmacol. 50:1995;489-496.
45. Lipsky P. Immunosuppression by D-penicillamine in vitro. Inhibition of human T lymphocyte proliferation by copper- or ceruloplasmin-dependent generation of hydrogen peroxide and protection by monocytes. J Clin Invest. 73:1984;53-56.
46. Aruoma OI, Halliwell B, Hoey BM, Butler J. The antioxidant action of taurine, hypotaurine and their metabolic precursors. Biochem J. 256:1988;251-255.
47. Held KD, Biaglow JE. Role of copper in the oxygen radical-mediated toxicity of the thiol-containing radioprotector dithiothreitol in mammalian cells. Radiat Res. 134:1993;375-382.
48. Polla BS, Donati Y, Kondo M, Tochon-Danguy HJ, Bonjour J-P. Protection from cellular oxidative injury and calcium intrusion by N-(2-mercaptoethyl)-1,3-propanediamine, WR 1065. Biochem Pharmacol. 40:1990;1469-1475.
49. Crampton MR. Acidity and hydrogen-bonding. Patai S. The Chemistry of the Thiol Group. 1974;379-416 John Wiley, London.
50. Smolin LA, Clark KF, Thoene JG, Gahl WA, Schneider JA. A comparison of the effectiveness of cysteamine and phosphocysteamine in elevating plasma cysteamine concentration and decreasing leukocyte free cystine in nephropathic cystinosis. Pediatr Res. 23:1988;616-620.
51. Corden BJ, Schulman JD, Schneider JA, Thoene JG. Adverse reactions to oral cysteamine use on nephropathic cystinosis. Dev Pharmacol Ther. 3:1981;25-30.